Identification of a Gene Expression Profile That Differentiates Between Ischemic and Nonischemic Cardiomyopathy

Background—Gene expression profiling refines diagnostic and prognostic assessment in oncology but has not yet been applied to myocardial diseases. We hypothesized that gene expression differentiates ischemic and nonischemic cardiomyopathy, demonstrating that gene expression profiling by clinical parameters is feasible in cardiology. Methods and Results—Affymetrix U133A microarrays of 48 myocardial samples from Johns Hopkins Hospital (JHH) and the University of Minnesota (UM) obtained (1) at transplantation or left ventricular assist device (LVAD) placement (end-stage; n=25), (2) after LVAD support (post-LVAD; n=16), and (3) from newly diagnosed patients (biopsy; n=7) were analyzed with prediction analysis of microarrays. A training set was used to develop the profile and test sets to validate the accuracy of the profile. An etiology prediction profile developed in end-stage JHH samples was tested in independent samples from both JHH and UM with 100% sensitivity and 100% specificity in end-stage samples and 33% sensitivity and 100% specificity in both post-LVAD and biopsy samples. The overall sensitivity was 89% (95% CI 75% to 100%), and specificity was 89% (95% CI 60% to 100%) over 210 random partitions of end-stage samples into training and test sets. Age, gender, and hemodynamic differences did not affect the profile’s accuracy in stratified analyses. Select gene expression was confirmed with quantitative polymerase chain reaction. Conclusions—Gene expression profiling accurately predicts cardiomyopathy etiology, is generalizable to samples from separate institutions, is specific to disease stage, and is unaffected by differences in clinical characteristics. This strongly supports ongoing efforts to incorporate expression profiling–based biomarkers in determining prognosis and response to therapy in heart failure.

[1]  Xinqiang Han,et al.  Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks. , 2004, Physiological genomics.

[2]  Stefan Kääb,et al.  Global gene expression in human myocardium—oligonucleotide microarray analysis of regional diversity and transcriptional regulation in heart failure , 2004, Journal of Molecular Medicine.

[3]  Edison T Liu,et al.  Microarrays and clinical investigations. , 2004, The New England journal of medicine.

[4]  R. Tibshirani,et al.  Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.

[5]  R. Verhaak,et al.  Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.

[6]  Raimond L Winslow,et al.  Gene expression profiles in end-stage human idiopathic dilated cardiomyopathy: altered expression of apoptotic and cytoskeletal genes. , 2004, Genomics.

[7]  J. Miyazaki,et al.  cDNA Array Hybridization Reveals Cardiac Gene Expression in Acute Ischemic Murine Hearts , 2001, Cardiovascular Drugs and Therapy.

[8]  M. Josephson,et al.  MADIT II (second Multicenter Automated Defibrillator Implantation Trial) debate: risk stratification, costs, and public policy. , 2003, Circulation.

[9]  Euan A Ashley,et al.  Novel Role for the Potent Endogenous Inotrope Apelin in Human Cardiac Dysfunction , 2003, Circulation.

[10]  M. Hori,et al.  Canine DNA array as a potential tool for combining physiology and molecular biology. , 2003, Circulation journal : official journal of the Japanese Circulation Society.

[11]  L. Miller,et al.  Alterations of gene expression in failing myocardium following left ventricular assist device support. , 2003, Physiological genomics.

[12]  L. Kedes,et al.  Gene expression profiling--a new approach in the study of myocardial ischemia. , 2003, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[13]  James Fang,et al.  Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. , 2003, Journal of the American College of Cardiology.

[14]  W. Koch,et al.  Differential gene expression and genomic patient stratification following left ventricular assist device support. , 2003, Journal of the American College of Cardiology.

[15]  Christopher M O'Connor,et al.  Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. , 2003, Journal of the American College of Cardiology.

[16]  E. Lakatta,et al.  Sex- and age-dependent human transcriptome variability: Implications for chronic heart failure , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  C. D. dos Remedios,et al.  Activation of signal transducer and activator of transcription (STAT) pathways in failing human hearts. , 2003, Cardiovascular research.

[18]  M. Le Cunff,et al.  Transcriptomal analysis of failing and nonfailing human hearts. , 2003, Physiological genomics.

[19]  M. Radmacher,et al.  Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.

[20]  Sayan Mukherjee,et al.  Estimating Dataset Size Requirements for Classifying DNA Microarray Data , 2003, J. Comput. Biol..

[21]  Atul Butte,et al.  The use and analysis of microarray data , 2002, Nature Reviews Drug Discovery.

[22]  S. Cook,et al.  DNA Microarrays : Implications for Cardiovascular Medicine , 2002 .

[23]  D. Latchman,et al.  Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. , 2002, American journal of physiology. Heart and circulatory physiology.

[24]  Y. Ladilov,et al.  Role of protein phosphatases in hypoxic preconditioning. , 2002, American journal of physiology. Heart and circulatory physiology.

[25]  Jianbo Li,et al.  The gene expression fingerprint of human heart failure , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[26]  George C Tseng,et al.  Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. , 2002, Physiological genomics.

[27]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[28]  Paul D Allen,et al.  Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. , 2002, The American journal of pathology.

[29]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  C. O'connor,et al.  A standardized definition of ischemic cardiomyopathy for use in clinical research. , 2002, Journal of the American College of Cardiology.

[31]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[32]  M. Drazner,et al.  Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. , 2001, Journal of the American College of Cardiology.

[33]  Towbin Ja,et al.  Molecular genetics of left ventricular dysfunction. , 2001 .

[34]  J. Towbin,et al.  Molecular genetics of left ventricular dysfunction. , 2001, Current molecular medicine.

[35]  D. Lyn,et al.  Gene expression profile in mouse myocardium after ischemia. , 2000, Physiological genomics.

[36]  R H Hruban,et al.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. , 2000, The New England journal of medicine.

[37]  S. Vanni,et al.  Selective upregulation of cardiac endothelin system in patients with ischemic but not idiopathic dilated cardiomyopathy: endothelin-1 system in the human failing heart. , 2000, Circulation research.

[38]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[39]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[40]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  F. Follath,et al.  Etiology and response to drug treatment in heart failure. , 1998, Journal of the American College of Cardiology.

[42]  C. di Loreto,et al.  Myocyte proliferation in end-stage cardiac failure in humans. , 1998, Proceedings of the National Academy of Sciences of the United States of America.